| Alisertib studied in …STUDIED_INderived61 of 61show fewer |
|---|
| → studied in | NCT07706179Phase 2 · not yet recruiting Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer · 61 trials list this drug (6 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02860000Phase 2 · completed Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer · 61 trials list this drug (6 active) | — | — | Malignant Breast Neoplasm,Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07465757Phase 2 · recruiting A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) · 61 trials list this drug (6 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01695941Phase 1 · active not recruiting Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma · 61 trials list this drug (6 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02114229Phase 2 · active not recruiting Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors · 61 trials list this drug (6 active) | — | — | Rhabdoid Tumor,Atypical Teratoid/Rhabdoid Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06095505Phase 2 · recruiting A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer · 61 trials list this drug (6 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04085315Phase 1 · completed Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer · 61 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06369285Phase 2 · recruiting A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer · 61 trials list this drug (6 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04479306Phase 1 · completed Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer · 61 trials list this drug (6 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04555837Phase 1/Phase 2 · completed Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer · 61 trials list this drug (6 active) | — | — | Malignant Solid Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01848067Phase 1/Phase 2 · completed Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer · 61 trials list this drug (6 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02186509Phase 1 · completed Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas · 61 trials list this drug (6 active) | — | — | Adult Mixed Glioma,Adult Anaplastic Astrocytoma,Adult Anaplastic Ependymoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02187991Phase 2 · completed Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer · 61 trials list this drug (6 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02293005Phase 2 · completed Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma · 61 trials list this drug (6 active) | — | — | Malignant Mesothelioma,Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01924260Phase 1 · completed Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer · 61 trials list this drug (6 active) | — | — | Adult Solid Neoplasm,Malignant Pancreatic Neoplasm,Pancreatic Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02719691Phase 1 · completed Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer · 61 trials list this drug (6 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00853307Phase 2 · completed MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma · 61 trials list this drug (6 active) | — | — | Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02530619NA · unknown Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia · 61 trials list this drug (6 active) | — | — | Acute Megakaryoblastic Leukemia,Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01154816Phase 2 · completed Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia · 61 trials list this drug (6 active) | — | — | Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor,Hepatoblastoma,Childhood Kidney Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02560025Phase 2 · completed Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML · 61 trials list this drug (6 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02327169Phase 1 · completed A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies · 61 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02259010Phase 1 · completed A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma · 61 trials list this drug (6 active) | — | — | Solid Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01601535Phase 1/Phase 2 · completed Study of MLN8237 in Combination With Irinotecan and Temozolomide · 61 trials list this drug (6 active) | — | — | Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01637961Phase 2 · completed Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus · 61 trials list this drug (6 active) | — | — | Uterine Corpus Sarcoma,Uterine Corpus Leiomyosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01639911Phase 1 · completed Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors · 61 trials list this drug (6 active) | — | — | Head and Neck Neoplasm,Malignant Breast Neoplasm,Malignant Thoracic Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02367352Phase 1 · terminated Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors · 61 trials list this drug (6 active) | — | — | Solid Neoplasm,Malignant Ovarian Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01898078Phase 1 · completed Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas · 61 trials list this drug (6 active) | — | — | Solid Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00697346Phase 1 · completed Study of MLN8237 in Participants With Advanced Hematological Malignancies · 61 trials list this drug (6 active) | — | — | Anaplastic Large Cell Lymphoma,Multiple Myeloma,Chronic Lymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02109328Phase 2 · completed Alisertib in Chemotherapy-pretreated Urothelial Cancer · 61 trials list this drug (6 active) | — | — | Transitional Cell Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01844583Phase 1 · completed Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib · 61 trials list this drug (6 active) | — | — | Solid Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00651664Phase 1 · completed A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies · 61 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01512758Phase 1 · completed A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas · 61 trials list this drug (6 active) | — | — | Solid Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00500903Phase 1 · completed A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors · 61 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00962091Phase 1 · completed Study of MLN8237 in Participants With Advanced Solid Tumors · 61 trials list this drug (6 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01094288Phase 1 · completed A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen · 61 trials list this drug (6 active) | — | — | Solid Neoplasm,Prostate Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01897012Phase 1 · completed Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas · 61 trials list this drug (6 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Burkitt Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01923337Phase 1 · completed Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer · 61 trials list this drug (6 active) | — | — | Adult Solid Neoplasm,Colon Mucinous Adenocarcinoma,Malignant Colon Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02038647Phase 2 · completed Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) · 61 trials list this drug (6 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02214147Phase 1 · completed Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function · 61 trials list this drug (6 active) | — | — | Solid Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01714947Phase 1 · completed Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib · 61 trials list this drug (6 active) | — | — | Solid Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02319018Phase 1 · completed Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors · 61 trials list this drug (6 active) | — | — | Malignant Digestive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02219789Phase 1 · completed Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery · 61 trials list this drug (6 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01540682Phase 1 · completed MLN8237 in Head and Neck Cancer · 61 trials list this drug (6 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01482962Phase 3 · completed Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma · 61 trials list this drug (6 active) | — | — | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01812005Phase 2 · terminated Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · 61 trials list this drug (6 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Grade 3 Follicular Lymphoma,Mantle Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01091428Phase 2 · completed Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer · 61 trials list this drug (6 active) | — | — | Breast Carcinoma,Malignant Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00830518Phase 2 · completed A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome · 61 trials list this drug (6 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01567709Phase 1 · completed Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma · 61 trials list this drug (6 active) | — | — | Anaplastic Large Cell Lymphoma,Hairy Cell Leukemia,Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03005262no longer available MLN8237 for a Subject With Adenocarcinoma of the Prostate · 61 trials list this drug (6 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00807495Phase 2 · completed Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma · 61 trials list this drug (6 active) | — | — | T-Cell Non-Hodgkin Lymphoma,Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01397825Phase 1/Phase 2 · completed MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine · 61 trials list this drug (6 active) | — | — | Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01799278Phase 2 · completed A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer · 61 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01677559Phase 1 · completed Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies · 61 trials list this drug (6 active) | — | — | Adenocarcinoma,Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01653028Phase 2 · completed Alisertib in Treating Patients With Advanced or Metastatic Sarcoma · 61 trials list this drug (6 active) | — | — | Liposarcoma,Malignant Peripheral Nerve Sheath Tumor,Soft Tissue Sarcoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02700022Phase 1 · terminated A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas · 61 trials list this drug (6 active) | — | — | Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02812056Phase 1 · withdrawn Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies · 61 trials list this drug (6 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01779843Phase 1 · completed Alisertib for Acute Myeloid Leukemia · 61 trials list this drug (6 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01045421Phase 1/Phase 2 · completed Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies · 61 trials list this drug (6 active) | — | — | Malignant Breast Neoplasm,Head and Neck Squamous Cell Carcinoma,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01034553Phase 1/Phase 2 · completed Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma · 61 trials list this drug (6 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01466881Phase 2 · completed Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma · 61 trials list this drug (6 active) | — | — | Anaplastic Large Cell Lymphoma,Adult Non-Hodgkin Lymphoma,Adult T-Cell Leukemia/Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02444884Phase 1 · completed MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors · 61 trials list this drug (6 active) | — | — | Childhood Solid Neoplasm,Neuroblastoma | 1 | Observed | clinicaltrials | graph → |